Patients at an increased risk of having glucose-6-dehydrogenase (G6PD), such as African or Mediterranean patients, should be screened before being prescribed Krystexxa because of the increased risk of developing methemoglobinemia or hemolysis [29]. This evidence concerns the gene G6PD and methemoglobinemia.